Phagocytosis of Apoptotic Cells Required for Mer Tyrosine Kinase

Total Page:16

File Type:pdf, Size:1020Kb

Phagocytosis of Apoptotic Cells Required for Mer Tyrosine Kinase Auto-Oxidation and Oligomerization of Protein S on the Apoptotic Cell Surface Is Required for Mer Tyrosine Kinase-Mediated Phagocytosis of Apoptotic Cells This information is current as of October 2, 2021. Hiroshi Uehara and Emily Shacter J Immunol 2008; 180:2522-2530; ; doi: 10.4049/jimmunol.180.4.2522 http://www.jimmunol.org/content/180/4/2522 Downloaded from References This article cites 53 articles, 17 of which you can access for free at: http://www.jimmunol.org/content/180/4/2522.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 2, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Auto-Oxidation and Oligomerization of Protein S on the Apoptotic Cell Surface Is Required for Mer Tyrosine Kinase-Mediated Phagocytosis of Apoptotic Cells Hiroshi Uehara and Emily Shacter1 Prompt phagocytosis of apoptotic cells prevents inflammatory and autoimmune responses to dying cells. We have previously shown that the blood anticoagulant factor protein S stimulates phagocytosis of apoptotic human B lymphoma cells by human monocyte-derived macrophages. In this study, we show that protein S must first undergo oxidative activation to stimulate phagocytosis. Binding of human protein S to apoptotic cells or to phosphatidylserine multilamellar vesicles promotes auto- oxidation of Cys residues in protein S, resulting in covalent, disulfide-linked dimers and oligomers that preferentially bind to and activate the human Mer tyrosine kinase (MerTK) receptor on the macrophages. The prophagocytic activity of protein S is eliminated when disulfide-mediated oligomerization is prevented, or when MerTK is blocked with neutralizing Abs. Downloaded from Protein S oligomerization is independent of phospholipid oxidation. The data suggest that membranes containing phospha- tidylserine serve as a scaffold for protein S-protein S interactions and that the resulting auto-oxidation and oligomerization is required for the prophagocytic activity of protein S. In this way, apoptotic cells facilitate their own uptake by macro- phages. The requirement for oxidative modification of protein S can explain why this abundant blood protein does not constitutively activate MerTK in circulating monocytes and tissue macrophages. The Journal of Immunology, 2008, 180: 2522–2530. http://www.jimmunol.org/ poptosis is a physiological form of cell death that plays outer leaflet of the plasma membrane (10, 11). The PS exposure is an essential role in tissue and organ development and thought to be essential for the recognition and uptake of apoptotic A homeostasis in multicellular organisms. Rapid removal cells by phagocytes (12–14). of apoptotic cells by macrophages and certain types of neighboring Several different macrophage receptors have been identified as cells before the loss of plasma membrane integrity prevents the being involved in the phagocytosis of apoptotic cells (reviewed in leakage of potentially toxic and immunogenic cellular contents and Ref. 15). These include a PS receptor, integrins, CD14, CD36, and thereby prevents inflammation and autoimmune responses to cell receptors for oxidized low-density lipoprotein. One key macro- death (1, 2). This is thought to be one of the main physiological phage receptor is Mer tyrosine kinase (MerTK), which is a mem- by guest on October 2, 2021 advantages of death through apoptosis instead of necrosis, in ber of the TAM family of receptor tyrosine kinases (16). It is which cellular macromolecules may leak out and stimulate an in- expressed on epithelial cells and monocytic cells (17), both of flammatory response before removal of the cells from the tissue (3, which have phagocytic activity. The essential role of MerTK has 4). Engulfment of apoptotic cells by macrophages also triggers been demonstrated for the phagocytosis of photoreceptor outer production of anti-inflammatory and immunosuppressive cyto- segment cells by retinal pigment epithelium cells (18, 19). kines, further limiting an immune response (5, 6). Studies using In addition to these phagocyte surface molecules, a number of gene knockout mice have shown an association between autoim- soluble molecules have been identified that may control the inter- mune disease and abnormal clearance of apoptotic cells (7, 8). action between apoptotic cells and phagocytes (2). These include The removal of apoptotic cells involves apoptotic cell surface protein S, MFG-E8, gas6, C1q, mannose-binding lectin, throm- ␤ molecules, phagocyte receptors, and soluble factors that modulate bospondin, pentraxin, 2-glycoprotein I, and surfactant proteins A cell recognition and uptake (1, 9). Upon induction of apoptosis, and D. Opsonization of target cells with bridging molecules may cells lose the phospholipid asymmetry normally found in the expand the repertoire of potential phagocytic targets by allowing plasma membrane and expose phosphatidylserine (PS)2 on the classical phagocyte receptors that are customarily associated with infection and immunity to mediate recognition and uptake of ap- optotic cells and thereby limit the undesirable side effects from Laboratory of Biochemistry, Division of Therapeutic Proteins, Center for Drug Eval- uation and Research, Food and Drug Administration, Bethesda, MD 20892 exposure to dead cell debris (20, 21). We and others showed that the anticoagulant factor protein S is Received for publication June 28, 2007. Accepted for publication November 30, 2007. required for the efficient uptake of apoptotic lymphoma cells by The costs of publication of this article were defrayed in part by the payment of page macrophages in vitro (22, 23). Protein S, originally defined as an charges. This article must therefore be hereby marked advertisement in accordance anticoagulant protein that is a nonenzymatic cofactor for activated with 18 U.S.C. Section 1734 solely to indicate this fact. protein C, is a vitamin K-dependent, 68-kDa monomeric protein 1 Address correspondence and reprint requests to Dr. Emily Shacter, Center for Drug present at a concentration of ϳ25 ␮g/ml in the blood (24, 25). It Evaluation and Research, Food and Drug Administration, 29 Lincoln Drive, Building 29A, Room 2A-11, HFD-121, Bethesda, MD 20892-4555. E-mail address: [email protected] 2 Abbreviations used in this paper: PS, phosphatidylserine; MerTK, Mer tyrosine 2-methyl-propaimidaamide; (Ϯ)9-HODE, (Ϯ)-9-hydroxy-10E,12Z-octadecadienoic kinase; CFDA, carboxyfluorescein diacetate, succinimidyl ester mixed isomer; PI, acid; IAA, iodoacetamide; NEM, N-ethylmaleimide; TnCl, taurine chloramine; sMer, propidium iodide; PC, phosphatidylcholine; DOPS, dioleoyl PS; DOPC, dioleoyl PC; soluble Mer; LMV, large multilamellar vesicle; oxPLPS, oxidized PLPS; LDS, lith- PLPS, 1-palmitoyl-2-linoleoyl-sn-glycero-3-[phospho-L-serine]; AAPH, 2.2Ј-azobis- ium dodecyl sulfate. www.jimmunol.org The Journal of Immunology 2523 ϩ is known to bind to PS on cell surfaces in a Ca2 -dependent man- 30–50% apoptosis as assessed by two different techniques: Hoechst 33342 ner using a Gla domain at the N terminus of the protein. Aberrantly and PI staining followed by nuclear morphology assessment using fluo- low levels of protein S may lead to inefficient uptake of early rescence microscopy (4) or by two-color flow cytometry using a FACScan (BD Biosciences) following labeling of cells with FITC-annexin V in apoptotic cells and expose immune cells to potentially immuno- binding buffer (10 mM HEPES, 0.14 M NaCl, 5 mM KCl, 2.5 mM genic cellular contents and thus trigger an autoimmune response CaCl2, 1 mM MgCl2 (pH 7.4)) followed by addition of PI as described (26). Deficiencies in protein S, either hereditary or acquired previously (13). through autoantibody formation, lead to excess thrombosis (27) Modification of protein S with iodoacetamide (IAA), and are associated with autoimmune diseases such as systemic N-ethylmaleimide (NEM), or taurine chloramine (TnCl) lupus erythematosus (28, 29). The newly discovered role of protein S in stimulating the phagocytosis of apoptotic cells re- Protein S was covalently modified by incubating with 100 mM IAA or 10 mM NEM in PBS for 30 min at room temperature. The reaction was veals a novel functional link between the coagulation system stopped by passing the solution through a Sephadex G-25 desalting col- and autoimmunity (26). umn. TnCl was prepared by mixing 10 mM taurine with 2.5 mM HOCl, In this report, we investigated the biochemical and molecular which results in immediate and quantitative consumption of all of the mechanisms for stimulation of phagocytosis by protein S. We HOCl into TnCl (30). This solution was diluted to 0.5 mM TnCl in PBS containing 1.5 mM CaCl and incubated with protein S alone (0.25 mg/ml) or demonstrate that in order for protein S to serve as a prophagocytic 2 protein S bound to PS vesicles at 25°C for 1 h. The sulfhydryl-specific cross- molecule, it must bind to membranous PS, either on the surface of linking of protein S was performed in PBS containing 0.5 mM BM(PEO)2 apoptotic cells or in artificial phospholipids vesicles. Protein S then under the same condition as described for oxidation with TnCl. The reactions undergoes oligomerization through oxidation of cysteine residues were stopped by desalting with Sephadex G-25. and formation of intermolecular disulfide bonds. This oxidative Preparation of phospholipid vesicles Downloaded from activation of the protein is required for binding to and activation the macrophage MerTK.
Recommended publications
  • Vitamin K Dependent Actions of Gas6
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Digital.CSIC Vitamin K dependent actions of Gas6. Lola Bellido-Martín, Pablo García de Frutos Department of Cell Death and Proliferation, Institute for Biomedical Research of Barcelona, IIBB-CSIC-IDIBAPS, Barcelona, Spain. Correspondence to: Pablo García de Frutos, Institute for Biomedical Research of Barcelona (IIBB-CSIC-IDIBAPS), Roselló 161 p6, 08036 Barcelona, Spain Tel: +34 933632382 Fax: +34 933638301 Email: [email protected] Abstract GAS6 (growth arrest-specific gene 6) is the last addition to the family of plasma vitamin K- dependent proteins. Gas6 was cloned and characterized in 1993 and found to be similar to the plasma anticoagulant protein S. Soon after it was recognized as a growth factor-like molecule, as it interacted with receptor tyrosine kinases of the TAM family; Tyro3, Axl and MerTK. Since then, the role of Gas6, protein S and the TAM receptors has been found to be important in inflammation, hemostasis and cancer, making this system an interesting target in biomedicine. Gas6 employs a unique mechanism of action, interacting through its vitamin K- dependent Gla module with phosphatidylserine-containing membranes and through its carboxy-terminal LG domains with the TAM membrane receptors. The fact that these proteins are affected by anti-vitamin K therapy is discussed in detail. Article Outline I. Introduction. II. Gas6 structure. III. Cellular effects of Gas6. IV. Interaction with TAM receptor molecules and signal transduction in the Gas6/TAM ligand/receptor system. V. Role of the Gas6/TAM system in vascular biology.
    [Show full text]
  • Role of Vitamin K-Dependent Factors Protein S and GAS6 and TAM Receptors in SARS-Cov-2 Infection and COVID-19-Associated Immunothrombosis
    cells Review Role of Vitamin K-Dependent Factors Protein S and GAS6 and TAM Receptors in SARS-CoV-2 Infection and COVID-19-Associated Immunothrombosis Anna Tutusaus 1 , Montserrat Marí 1 , José T. Ortiz-Pérez 2,3 , Gerry A. F. Nicolaes 4, Albert Morales 1,5,* and Pablo García de Frutos 1,3,* 1 Department of Cell Death and Proliferation, IIBB-CSIC, IDIBAPS, 08036 Barcelona, Spain; [email protected] (A.T.); [email protected] (M.M.) 2 Clinic Cardiovascular Institute, Hospital Clinic Barcelona, 08036 Barcelona, Spain; [email protected] 3 Centro de Investigación Biomédica en Red sobre Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain 4 Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, 6200 MD Maastricht, The Netherlands; [email protected] 5 Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clínic, CIBEREHD, 08036 Barcelona, Spain * Correspondence: [email protected] (A.M.); [email protected] (P.G.d.F.); Tel.: +34-93-3638300 (A.M. & P.G.d.F.) Received: 2 September 2020; Accepted: 26 September 2020; Published: 28 September 2020 Abstract: The vitamin K-dependent factors protein S (PROS1) and growth-arrest-specific gene 6 (GAS6) and their tyrosine kinase receptors TYRO3, AXL, and MERTK, the TAM subfamily of receptor tyrosine kinases (RTK), are key regulators of inflammation and vascular response to damage. TAM signaling, which has largely studied in the immune system and in cancer, has been involved in coagulation-related pathologies. Because of these established biological functions, the GAS6-PROS1/TAM system is postulated to play an important role in SARS-CoV-2 infection and progression complications.
    [Show full text]
  • LY2801653 Is an Orally Bioavailable Multi-Kinase Inhibitor with Potent
    Invest New Drugs (2013) 31:833–844 DOI 10.1007/s10637-012-9912-9 PRECLINICAL STUDIES LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models S. Betty Yan & Victoria L. Peek & Rose Ajamie & Sean G. Buchanan & Jeremy R. Graff & Steven A. Heidler & Yu-Hua Hui & Karen L. Huss & Bruce W. Konicek & Jason R. Manro & Chuan Shih & Julie A. Stewart & Trent R. Stewart & Stephanie L. Stout & Mark T. Uhlik & Suzane L. Um & Yong Wang & Wenjuan Wu & Lei Yan & Wei J. Yang & Boyu Zhong & Richard A. Walgren Received: 19 October 2012 /Accepted: 3 December 2012 /Published online: 29 December 2012 # The Author(s) 2012. This article is published with open access at Springerlink.com Summary The HGF/MET signaling pathway regulates a of a potent, orally bioavailable, small-molecule inhibitor wide variety of normal cellular functions that can be subverted LY2801653 targeting MET kinase. LY2801653 is a type-II to support neoplasia, including cell proliferation, survival, ATP competitive, slow-off inhibitor of MET tyrosine kinase apoptosis, scattering and motility, invasion, and angiogenesis. with a dissociation constant (Ki) of 2 nM, a pharmacodynamic −1 MET over-expression (with or without gene amplification), residence time (Koff) of 0.00132 min and t1/2 of 525 min. aberrant autocrine or paracrine ligand production, and mis- LY2801653 demonstrated in vitro effects on MET pathway- sense MET mutations are mechanisms that lead to activation dependent cell scattering and cell proliferation; in vivo anti- of the MET pathway in tumors and are associated with poor tumor effects in MET amplified (MKN45), MET autocrine prognostic outcome.
    [Show full text]
  • Crystal Structure of the Kinase Domain of Mertk in Complex with AZD7762 Provides Clues for Structure-Based Drug Development
    International Journal of Molecular Sciences Article Crystal Structure of the Kinase Domain of MerTK in Complex with AZD7762 Provides Clues for Structure-Based Drug Development Tae Hyun Park 1,2 , Seung-Hyun Bae 1,3 , Seoung Min Bong 1, Seong Eon Ryu 2, Hyonchol Jang 1,3 and Byung Il Lee 1,3,* 1 Research Institute, National Cancer Center, Goyang, 10408 Gyeonggi, Korea; [email protected] (T.H.P.); [email protected] (S.-H.B.); [email protected] (S.M.B.); [email protected] (H.J.) 2 Department of Bioengineering, Hanyang University, 04763 Seoul, Korea; [email protected] 3 Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, 10408 Gyeonggi, Korea * Correspondence: [email protected]; Tel.: +82-31-920-2223; Fax: +82-31-920-2006 Received: 29 August 2020; Accepted: 21 October 2020; Published: 23 October 2020 Abstract: Aberrant tyrosine-protein kinase Mer (MerTK) expression triggers prosurvival signaling and contributes to cell survival, invasive motility, and chemoresistance in many kinds of cancers. In addition, recent reports suggested that MerTK could be a primary target for abnormal platelet aggregation. Consequently, MerTK inhibitors may promote cancer cell death, sensitize cells to chemotherapy, and act as new antiplatelet agents. We screened an inhouse chemical library to discover novel small-molecule MerTK inhibitors, and identified AZD7762, which is known as a checkpoint-kinase (Chk) inhibitor. The inhibition of MerTK by AZD7762 was validated using an in vitro homogeneous time-resolved fluorescence (HTRF) assay and through monitoring the decrease in phosphorylated MerTK in two lung cancer cell lines.
    [Show full text]
  • MERTK Antibody Catalog Number: MKT-101AP Lot Number: General Information
    FabGennix International, Inc. 9191 Kyser Way Bldg. 4 Suite 402 Frisco, TX 75033 Tel: (214)-387-8105, 1-800-786-1236 Fax: (214)-387-8105 Email: [email protected] Web: www.FabGennix.com Rabbit Polyclonal Anti-MERTK antibody Catalog Number: MKT-101AP Lot Number: General Information Product MERTK Antibody Description Affinity Purified Human cellular proto-oncogene (c- mer) mRNA Antibody C-epitope Accession # Uniprot: Q12866 GenBank: U08023.1 Verified Applications CM, ELISA, ICC, IF, IHC, IP, WB Species Cross Reactivity Human, Mouse, Rat Host Rabbit Immunogen Synthetic peptide taken within amino acid region 900-994 on MerTK protein. Alternative Nomenclature c mer proto oncogene tyrosine kinase antibody, cMER antibody, Eyk antibody, MER antibody, MER receptor tyrosine kinase antibody, MERK antibody, MERPEN antibody, Mertk antibody, MERTK c-mer proto-oncogene tyrosine kinase antibody, MGC133349 antibody, nmf12 antibody, Nyk antibody, Proto oncogene tyrosine protein kinase MER antibody, Receptor tyrosine kinase MerTK antibody, RP38 antibody, STK kinase antibody, Tyrosine-protein kinase Mer antibody Physical Properties Quantity 100 µg Volume 200 µl Form Affinity Purified Immunoglobulins Determinant C-epitope Immunoglobulin & Concentration 0.75 mg/ml IgG in antibody stabilization buffer Storage Store at -20⁰C for long term storage. Related Products Catalog # BIOTIN-Conjugated MKT100-BIOTIN FITC-Conjugated MKT100-FITC Antigenic Blocking Peptide P-MKT100 Western Blot Positive Control PC-MKT Tel: (214)-387-8105, 1-800-786-1236 Fax: (214)-387-8105 Email: [email protected] Web: www.FabGennix.com Recommended Dilutions DOT Blot 1:10,000 ELISA 1:10,000 Immunocytochemistry 1:200 Immunofluorescence 1:200 Immunohistochemistry 1:200 Immunoprecipitation 1:200 Western Blot 1:750 Application Verification: WB using MKT-101AP and human RPE cells.
    [Show full text]
  • Recombinant Human GAS6 (C-6His) Cat# C3282– 50 Ug Storage -20°C for 2 Years
    Datasheet Technical support: [email protected] Phone: 886-3-2870051 Ver.1 Date : 20180222 Recombinant Human GAS6 (C-6His) Cat# C3282– 50 ug Storage -20°C for 2 years INTFORMATION Product Name Recombinant Human GAS6 (C-6His) Cat NO. C3282 Size 50 ug Uniprot Q14393 Recombinant Human Growth Arrest-specific Protein 6 is produced by our Description Mammalian expression system and the target gene encoding Ala31-Ala678 is expressed with a 6His tag at the C-terminus. Purity Greater than 95% as determined by reducing SDS-PAGE. Endotoxin Less than 0.1 ng/ug (1 EU/ug) as determined by LAL test. Formulation Supplied as a 0.2 μm filtered solution of PBS, 10% Glycerol, pH 7.4. Molecular Weight 72.7 kDa Application Molecular Weight 80-90 kDa, reducing conditions Store at < -20°C, stable for 6 months after receipt. Please minimize freeze-thaw Storage cycles. AXLLG; AXLLGAXL stimulatory factor; AXSFAXL receptor tyrosine kinase ligand; Alias Gas6; GAS-6; growth arrest-specific 6; growth arrest-specific protein 6 GAS6 (Growth arrest-specific protein 6) is also known as AXL receptor tyrosine kinase ligand, AXLLG, is a multimodular protein that is up-regulated by a wide variety of cell types in response to growth arrest. Gas6 binds and induces signaling through the receptor tyrosine kinases Axl, Dtk, and Mer whose signaling is implicated in cell growth and survival, cell adhesion and cell Background migration. GAS6/AXL signaling plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses.
    [Show full text]
  • Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies Timothy M
    Published OnlineFirst May 26, 2016; DOI: 10.1158/0008-5472.CAN-16-0058 Cancer Therapeutics, Targets, and Chemical Biology Research Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies Timothy M. Shaver1,2, Brian D. Lehmann1,2, J. Scott Beeler1,2, Chung-I Li3, Zhu Li1,2, Hailing Jin1,2, Thomas P. Stricker4, Yu Shyr5,6, and Jennifer A. Pietenpol1,2 Abstract Triple-negative breast cancer (TNBC) and other molecularly discovered a clinical occurrence and cell line model of the target- heterogeneous malignancies present a significant clinical chal- able FGFR3–TACC3 fusion in TNBC. Expanding our analysis to lenge due to a lack of high-frequency "driver" alterations amena- other malignancies, we identified a diverse array of novel and ble to therapeutic intervention. These cancers often exhibit geno- known hybrid transcripts, including rearrangements between mic instability, resulting in chromosomal rearrangements that noncoding regions and clinically relevant genes such as ALK, affect the structure and expression of protein-coding genes. How- CSF1R, and CD274/PD-L1. The over 1,000 genetic alterations ever, identification of these rearrangements remains technically we identified highlight the importance of considering noncod- challenging. Using a newly developed approach that quantita- ing gene rearrangement partners, and the targetable gene tively predicts gene rearrangements in tumor-derived genetic fusions identified in TNBC demonstrate the need to advance material, we identified
    [Show full text]
  • Axl and Growth Arrest ^ Specific Gene 6 Are Frequently Overexpressed In
    Imaging, Diagnosis, Prognosis AxlandGrowthArrest^SpecificGene6AreFrequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme Markus Hutterer,1, 5 Pjotr Knyazev,5 ArianeAbate,1Markus Reschke,5 Hans Maier,2 Nadia Stefanova,1 Tatjana Knyazeva,5 Verena Barbieri,4 Markus Reindl,1Armin Muigg,1Herwig Kostron,3 Guenther Stockhammer,1and Axel Ullrich5,6 Abstract Purpose:The receptor tyrosine kinaseAxl has recently been identified as a critical element in the invasive properties of glioma cell lines. However, the effect of Axl and its ligand growth arrest ^ specific gene 6 (Gas6) in human gliomas is still unknown. Experimental Design: Axl and Gas6 expression was studied in 42 fresh-frozen and 79 paraffin- embedded glioma specimens by means of reverse transcription-PCR and immunohistochemistry. The prognostic value of Axl and Gas6 expression was evaluated using a population-based tissue microarray derived from a cohort of 55 glioblastoma multiforme (GBM) patients. Results: Axl and Gas6 were detectable in gliomas of malignancy gradesWHO 2 to 4. Moderate to highAxlmRNAexpressionwasfoundin61%,Axlproteinin55%,Gas6mRNAin81%,andGas6 proteinin74%of GBMsamples,respectively.GBMpatients withhigh Axlexpressionand Axl/Gas6 coexpression showed a significantly shorter time to tumor progression and an association with poorer overall survival. Comparative immunohistochemical studies showed that Axl staining was most pronounced in glioma cells of pseudopalisades and reactive astrocytes. Additionally, Axl/ Gas6 coexpression was observed in glioma cells and tumor vessels. In contrast, Axl staining was not detectable in nonneoplastic brain tissue and Gas6 was strongly expressed in neurons. Conclusions: In human gliomas, Axl and Gas6 are frequently overexpressed in both glioma and vascular cells and predict poor prognosis in GBM patients.
    [Show full text]
  • Effects of MERTK Inhibitors UNC569 and UNC1062 on the Growth of Acute Myeloid Leukaemia Cells YUKI KODA, MAI ITOH and SHUJI TOHDA
    ANTICANCER RESEARCH 38 : 199-204 (2018) doi:10.21873/anticanres.12208 Effects of MERTK Inhibitors UNC569 and UNC1062 on the Growth of Acute Myeloid Leukaemia Cells YUKI KODA, MAI ITOH and SHUJI TOHDA Department of Laboratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan Abstract. Background: MER proto-oncogene tyrosine kinase (AKT) and extracellular signal–regulated kinase (ERK) (1). (MERTK) is a receptor tyrosine kinase that affects cancer cell Overexpression of MERTK has been reported in acute proliferation. This study evaluated the effects of the synthetic myeloid leukaemia (AML) and acute lymphoblastic leukaemia MERTK inhibitors UNC569 and UNC1062 on in vitro growth (ALL) cells (2-4). However, the role of MERTK in leukaemia of acute myeloid leukaemia (AML) cells. Materials and cell growth remains unclear. Methods: Four AML cell lines expressing MERTK were treated Two small-molecule MERTK-selective inhibitors, UNC569 with UNC569 and UNC1062 and analyzed for cell and UNC1062, have been developed (5-7) that inhibit the proliferation, immunoblotting, and gene expression. The effects phosphorylation of MERTK by occupying its adenine pocket. of MERTK knockdown were also evaluated. Results: Treatment The effects of UNC1062 are more specific to MERTK than with the inhibitors suppressed cell growth and induced those of UNC569. UNC569 was reported to suppress ALL cell apoptosis in all cell lines. OCI/AML5 and TMD7 cells, in which growth in vitro (5). However, the effects of these inhibitors on MERTK was constitutively phosphorylated by autocrine AML cells and their molecular mechanisms have not been mechanisms, were highly susceptible to these inhibitors. The elucidated. treatment reduced the phosphorylation of MERTK and its down- To elucidate the role of MERTK in the growth of AML stream signalling molecules, v-akt murine thymoma viral cells and the molecular mechanism of action of these MERTK oncogene homolog 1 (AKT) and extracellular signal-regulated inhibitors, we evaluated the effects of these MERTK inhibitors kinase (ERK).
    [Show full text]
  • Mertk Regulates Thymic Selection of Autoreactive T Cells
    MerTK regulates thymic selection of autoreactive T cells Mark A. Walleta, Rafael R. Floresa, Yaming Wanga, Zuoan Yia, Charles J. Krogera, Clayton E. Mathewsb, H. Shelton Earpc,d, Glenn Matsushimaa,c,e, Bo Wanga, and Roland Tischa,c,1 aDepartment of Microbiology and Immunology, cUNC Lineberger Comprehensive Cancer Center, dDepartment of Medicine and Pharmacology, eUNC Neuroscience Center, University of North Carolina, Chapel Hill, NC 27599-7020; and bDepartment of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL 32610 Communicated by Hugh O. McDevitt, Stanford University, Stanford, CA, January 23, 2009 (received for review September 30, 2008) T cell-mediated autoimmune diseases such as type 1 diabetes (T1D) Our group and others demonstrated that the Mer tyrosine are believed to be the result in part of inefficient negative selection kinase (MerTK) negatively regulates antigen presenting cells of self-specific thymocytes. However, the events regulating thymic (APC) such as DC and macrophages (M␾) (18–21). MerTK negative selection are not fully understood. In the current study, belongs to a family of receptor tyrosine kinases (RTKs) con- we demonstrate that nonobese diabetic (NOD) mice lacking ex- sisting of Axl and Tyro3 (22, 23). Mice lacking expression of all pression of the Mer tyrosine kinase (MerTK) have reduced inflam- 3 RTKs have hyperactive APC in the periphery, resulting in mation of the pancreatic islets and fail to develop diabetes. systemic autoimmunity characterized by T cell infiltrates in Furthermore, NOD mice deficient in MerTK expression (Mer؊/؊) several tissues (24). In addition to DC and M␾, MerTK is exhibit a reduced frequency of ␤ cell-specific T cells independent of expressed by NK T cells, NK cells, epithelia and endothelia cell immunoregulatory effectors.
    [Show full text]
  • GAS6 Expression Identifies High-Risk Adult AML Patients
    Leukemia (2014) 28, 1252–1258 & 2014 Macmillan Publishers Limited All rights reserved 0887-6924/14 www.nature.com/leu ORIGINAL ARTICLE GAS6 expression identifies high-risk adult AML patients: potential implications for therapy SP Whitman1, J Kohlschmidt1,2, K Maharry1,2, S Volinia3, K Mro´zek1, D Nicolet1,2, S Schwind1, H Becker1, KH Metzeler1, JH Mendler1, A-K Eisfeld1, AJ Carroll4, BL Powell5, TH Carter6, MR Baer7, JE Kolitz8, I-K Park1, RM Stone9, MA Caligiuri1,10, G Marcucci1,10 and CD Bloomfield1,10 Emerging data demonstrate important roles for the TYRO3/AXL/MERTK receptor tyrosine kinase (TAM RTK) family in diverse cancers. We investigated the prognostic relevance of GAS6 expression, encoding the common TAM RTK ligand, in 270 adults (n ¼ 71 agedo60 years; n ¼ 199 aged X60 years) with de novo cytogenetically normal acute myeloid leukemia (CN-AML). Patients expressing GAS6 (GAS6 þ ), especially those aged X60 years, more often failed to achieve a complete remission (CR). In all patients, GAS6 þ patients had shorter disease-free (DFS) and overall (OS) survival than patients without GAS6 expression (GAS6 À ).Afteradjustingforotherprognosticmarkers,GAS6 þ predicted CR failure (P ¼ 0.02), shorter DFS (P ¼ 0.004) and OS (P ¼ 0.04). To gain further biological insights, we derived a GAS6-associated gene-expression signature (Po0.001) that in GAS6 þ patients included overexpressed BAALC and MN1, known to confer adverse prognosis in CN-AML, and overexpressed CXCL12, encoding stromal cell-derived factor, and its receptor genes, chemokine (C-X-C motif) receptor 4 (CXCR4)and CXCR7. This study reports forthefirsttimethatGAS6 expression is an adverse prognostic marker in CN-AML.
    [Show full text]
  • Mertk Inhibition Is a Novel Therapeutic Approach for Glioblastoma Multiforme
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 5, No. 5 MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme Kristina H. Knubel1, Ben M. Pernu1, Alexandra Sufit1, Sarah Nelson1, Angela M. Pierce1, Amy K. Keating1 1 Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA Correspondence to: Amy K Keating, email: [email protected] Keywords: MerTK, Axl, glioma, Foretinib, intracranial model Received: January 16, 2014 Accepted: March 10, 2014 Published: March 12, 2014 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT: Glioblastoma is an aggressive tumor that occurs in both adult and pediatric patients and is known for its invasive quality and high rate of recurrence. Current therapies for glioblastoma result in high morbidity and dismal outcomes. The TAM subfamily of receptor tyrosine kinases includes Tyro3, Axl, and MerTK. Axl and MerTK exhibit little to no expression in normal brain but are highly expressed in glioblastoma and contribute to the critical malignant phenotypes of survival, chemosensitivity and migration. We have found that Foretinib, a RTK inhibitor currently in clinical trial, inhibited phosphorylation of TAM receptors, with highest efficacy against MerTK, and blocked downstream activation of Akt and Erk in adult and pediatric glioblastoma cell lines, findings that are previously unreported. Survival, proliferation, migration, and collagen invasion were hindered in vitro. Foretinib treatment in vivo abolished MerTK phosphorylation and reduced tumor growth 3-4 fold in a subcutaneous mouse model.
    [Show full text]